Singapore HSA + the BPC-157 ban — strictest peptide regime in SEA
Singapore's Health Sciences Authority (HSA) operates the strictest research-peptide framework in Southeast Asia, comparable to TGA Australia in rigour. HSA explicitly banned BPC-157 in 2019 — the only national regulator to specifically schedule it as a Health Products Act prohibited substance. Combined with Singapore's aggressive customs enforcement and small geography, the HSA framework makes Singapore one of the riskiest jurisdictions globally for peptide imports. This article documents the framework and the specific BPC-157 ban that affects every Singapore researcher.
HSA was established in 2001 to consolidate Singapore's pharmaceutical and biomedical regulation. Operating under the Health Products Act (Cap 122D, 2007) and the Medicines Act (Cap 176, 1975), HSA registers therapeutic products through the New Drug Application (NDA) process and supervises imports. Singapore Customs cooperate closely with HSA on pharmaceutical-class import enforcement. The Health Products Act's Schedule 1 lists prohibited products; Schedule 2 lists controlled products requiring authorisation.
In 2019, HSA explicitly added BPC-157 to the prohibited products list — the only national regulator globally to schedule BPC-157 by name. The notice cited "no clinical evidence of safety or efficacy" and "concern about misuse for performance enhancement." The ban applies to all formulations including injectable, oral, and topical. Importing BPC-157 to Singapore is illegal under the Health Products Act regardless of research-use-only labelling.
For other research peptides (TB-500, GHK-Cu, Selank, Semax, Epithalon, etc.), the HSA framework treats them as unregistered therapeutic products. Imports for personal use require either: (a) a Health Products import permit (only granted for HSA-registered products — research peptides do not qualify), or (b) a Therapeutic Products import licence (requires manufacturer / distributor registration). The personal-use exception under the Medicines Act allows individuals to import a 3-month supply of an HSA-registered product with prescription — research peptides without HSA registration cannot use this exception.
Singapore Customs interception rates for peptide shipments to Singapore are among the highest globally. HSA cooperates with customs on intelligence sharing for known international peptide vendors. Operator-curated vendor data shows interception rates >50% for Singapore-bound research peptide shipments. The combination of small geography (single customs entry point, Changi Airport SIN) and aggressive enforcement makes Singapore the most challenging SEA market for cross-border peptide buying.
Penalties under the Health Products Act are significant: importing prohibited products (including BPC-157) carries fines up to S$500,000 (~US$370,000) and imprisonment up to 5 years. Importing unregistered therapeutic products without permit carries fines up to S$50,000 and imprisonment up to 2 years. Individual buyer prosecution is rare in practice but the legal exposure is substantial.
For institutional researchers in Singapore — A*STAR, NUS, NTU, Duke-NUS — the legitimate pathway is the Clinical Trials Certificate (CTC) under the Health Products Regulations. Singapore's research infrastructure is well-developed; institutional procurement through these pathways covers most academic peptide research. The CTC pathway specifically excludes BPC-157 since 2019; institutional research on BPC-157 in Singapore is now blocked.
For non-institutional Singapore researchers — biohackers, recreational athletes — the practical reality is: HSA framework + Singapore Customs cooperation + small geography make Singapore the most regulatory-exposed SEA jurisdiction. The recommended posture for Singapore residents is institutional research only; personal-use importation of peptides (especially BPC-157) carries genuine legal risk. Singapore researchers without institutional access typically cannot legally pursue research peptide work.
✓Pros
- HSA framework is well-documented and predictable
- Institutional CTC pathway through A*STAR, NUS, NTU, Duke-NUS is mature for non-BPC-157 research
- Singapore research infrastructure among best in SEA
×Cons
- BPC-157 explicitly banned since 2019 — the only national jurisdiction to do so
- HSA enforces against unregistered therapeutic products with significant penalties
- Singapore Customs interception rates >50% for cross-border peptide shipments
- Small geography means single customs entry point — Changi SIN — concentrates inspection
- No SG-domestic vendors; all imports cross-border
Is BPC-157 really banned in Singapore?
Yes — explicitly. HSA added BPC-157 to the prohibited products list in 2019 under the Health Products Act. Singapore is the only national regulator to specifically schedule BPC-157 by name. The ban applies to all formulations including injectable, oral, and topical.
What if I order BPC-157 to Singapore anyway?
Singapore Customs interception rates for peptide shipments are >50% per operator-curated vendor data. Importing BPC-157 specifically is a Health Products Act offence with penalties up to S$500,000 fine + 5 years imprisonment. Individual buyer prosecution is rare but legal exposure is substantial.
Are other peptides also banned?
Other research peptides (TB-500, GHK-Cu, Selank, Semax, Epithalon) are not specifically scheduled but treated as unregistered therapeutic products. Importing them requires HSA permit which is not granted for research-chemical purposes. The legal exposure is lower than BPC-157 but not zero.
Can institutional researchers in Singapore work with peptides?
Yes for non-BPC-157 peptides via the Clinical Trials Certificate (CTC) pathway under Health Products Regulations. A*STAR, NUS, NTU, Duke-NUS use this pathway routinely. BPC-157 specifically is excluded from CTC since 2019 — institutional BPC-157 research is now blocked in Singapore.
Why did HSA single out BPC-157?
The 2019 notice cited "no clinical evidence of safety or efficacy" and "concern about misuse for performance enhancement." BPC-157 was the most-traded research peptide globally, so HSA's targeted ban reflects the high-volume nature of the compound. WADA followed in 2022 with named-explicit listing under S0.
Where should Singapore-resident researchers get peptides?
Institutional pathway only. Non-institutional research peptide work in Singapore carries genuine legal risk under Health Products Act. Singapore residents seeking personal-use research access typically cannot legally pursue this — Singapore is among the most restrictive jurisdictions globally.